Challenges in compression testing of 3D angle-interlocked woven-glass fabric-reinforced polymeric composites.

This paper describes the challenges in using testing standards such as D6641/D6641M-14, for determination of compressive strength of 3D angle interlocked glass fabric reinforced polymeric composites (3D-FRPC). It makes use of both experimental investigation and finite element analysis. The experimental investigation involved testing both 2D and 3D-FRPC using ASTM D6641/D6641M-14 and subsequent scanning electron microscopic imaging of failed specimens to reveal the stress state at failure. This was further evaluated using laminate level finite element (FE) analysis. The FE analysis required input of effective orthotropic elastic material properties of 3D-FRPC, which were determined by customizing a recently developed micro-mechanical model. The paper sheds new light on compressive failure of 3D angle interlocked glass fabric composites, as only scarce data is available in literature about this class of materials. It showed that although the tests produce acceptable strength values the internal failure mechanisms change significantly and the standard deviation (SD) and coefficient of variance (COV) of 3D-FRPC comes out to be much higher than that of 2D-FRPC. Moreover, while reporting and using the test data some additional information about the 3D-fabric architecture, such as the direction of angle interlocking fabric needs to be specified. This was because, for 3D angle interlocking of fabric along warp direction, the strength values obtained in the warp and weft direction were significantly different from each other. The study also highlights that due to complex weave architecture it is not possible to achieve comparable volume fractions with 2D and 3D fabric reinforced composites using similar manufacturing parameters for the vacuum assisted resin infusion process. Thus, the normalized compressive strength values (normalized with respect to volume fraction) are the highest for 3D-FRPC when measured along the warp direction, they are at an intermediate level for 2D-FRPC and the lowest for 3D-FRPC, when measured in the weft direction.DelPHE 780 Project grant (DFID UK

Off-Axis and On-Axis Performance of Novel Acrylic Thermoplastic (Elium®) 3D Fibre-Reinforced Composites under Flexure Load

The flexure response of novel thermoplastic (Elium®) 3D fibre-reinforced composites (FRC) was evaluated and compared with a conventional thermoset (Epolam®)-based 3D-FRC. Ten different types of sample 3D-FRC were prepared by varying fibre orientations, i.e., 0°, 30°, 45°, 60° and 90°, and resin system, i.e., thermoplastic and thermoset. The bending characteristics and failure mechanisms were determined by conducting a three-point bend test. Results elucidate that The flexure response of novel thermoplastic (Elium®) 3D fibre-reinforced composites (FRC) was evaluated and compared with a conventional thermoset (Epolam®)-based 3D-FRC. Ten different types of sample 3D-FRC were prepared by varying fibre orientations, i.e., 0°, 30°, 45°, 60° and 90°, and resin system, i.e., thermoplastic and thermoset. The bending characteristics and failure mechanisms were determined by conducting a three-point bend test. Results elucidate that the on-axis specimens show linear response and brittle failure; in contrast, the off-axis specimens depicted highly The flexure response of novel thermoplastic (Elium®) 3D fibre-reinforced composites (FRC) was evaluated and compared with a conventional thermoset (Epolam®)-based 3D-FRC. Ten different types of sample 3D-FRC were prepared by varying fibre orientations, i.e., 0°, 30°, 45°, 60° and 90°, and resin system, i.e., thermoplastic and thermoset. The bending characteristics and failure mechanisms were determined by conducting a three-point bend test. Results elucidate that the on-axis specimens show linear response and brittle failure; in contrast, the off-axis specimens depicted highly nonlinear response and ductile failure. The thermoplastic on-axis specimen exhibited almost similar flexure strength; in comparison, the off-axis specimens show ~17% lower flexure strength compared to thermoset 3D-FRC. Thermoplastic 3D-FRC shows ~40% higher energy absorption, ~23% lower flexure modulus and ~27% higher flexure strains as compared to its thermoset counterpart

Predicting the effect of voids on mechanical properties of woven composites.

An accurate yet easy to use methodology for determining the effective mechanical properties of woven fabric reinforced composites is presented. The approach involves generating a representative unit cell geometry based on randomly selected 2D orthogonal slices from a 3D X-ray micro-tomographic scan. Thereafter, the finite element mesh is generated from this geometry. Analytical and statistical micromechanics equations are then used to calculate effective input material properties for the yarn and resin regions within the FE mesh. These analytical expressions account for the effect of resin volume fraction within the yarn (due to infiltration during curing) as well as the presence of voids within the composite. The unit cell model is then used to evaluate the effective properties of the composite.DelPHE 780 Project funded by UK Department of International Development (DFID), through British Council managed DelPHE scheme

Bearing performance and damage characteristics of rein-infused thermoplastic 3D woven composites bolted joints

This paper presents a comprehensive study on the single-bolt single-shear (SBSS) and double-bolt single shear (DBSS) lap joint performance of resin-infused thermoplastic 3D fibre-reinforced composite (FRC) in on-axis (0°and 90°) and off-axis (45°) configurations. The bearing performance and failure mechanisms are compared with thermoset 3D-FRC. The resin-infused thermoplastic 3D-FRC bolted joint shows improved bearing performance in terms of higher ultimate bearing strength, stiffness loss strength, and reduced damage severity than its thermoset counterpart. Additionally, this paper presents a detailed study on the intermediate and final failure mechanisms, obtained from scanning electron microscopy of the interrupted and ultimate bearing tests, to understand damage progression in SBSS and BDSS lap joints at the submicron level. The major damage characteristics of a thermoplastic 3D-FRC bolted joint include plastic deformation and plastic kinking at the hole front tip, which improve the bearing capacity and reduce stress concentration, damage severity, and its deleterious effects

Multiscale damage modelling of 3D woven composites under static and impact loads

A multiscale progressive damage modelling methodology for 3-dimensional (3D) woven composites is presented. The proposed methodology is generic and can be implemented in most finite element software to create a digital twin for simulation of damage response. It uses 3D solid element (reduced integration) representation of the part for global analysis, while the local damage response, as well as matrix nonlinearity is modelled using a mesoscale constitutive unit-cell model of 3D woven composite consisting of idealised regions of polymer matrix and impregnated yarns. The idealised unit-cell model is defined based on realistic input from X-ray tomography of the 3D woven composite part and the micro-level constituent properties of the matrix and fibres. The damage model has been validated using quasi-static tensile/compression tests as well as dynamic drop-weight impact tests for both thermoset (epoxy) and thermoplastic (Elium) 3D woven composites. These simulations successfully demonstrate the accuracy and efficiency of the model for both 3D-textile composites.The authors would like to acknowledge the financial support provided by Universiti Teknologi PETRONAS (grant number 015LC0-197). The authors would also like to acknowledge the support of Dr. Pierre Gerard from Arkema and Dr. Sharp Keith from TexTech industries in acquiring Elium® resin and 3D fabric for this research work, Dr. Faiz Ahmad and Advance Functional Material (AFM) lab Universiti Teknologi PETRONAS in providing the facility for the fabrication of 3D woven composites

Identification of an effective nondestructive technique for bond defect determination in laminate composites—A technical review

Laminate composites are commonly used for the production of critical mechanical structures and components such as wind turbine blades, helicopter rotors, unmanned aerial vehicle wings and honeycomb structures for aircraft wings. During the manufacturing process of these composite structures, zones or areas with weak bond strength are always issues, which may affect the strength and performance of components. The identification and quantification of these zones are always challenging and necessary for the mass production. Non-destructive testing methods available, including ultrasonic A, B, and C-Scan, laser shearography, X-ray tomography, and thermography can be useful for the mentioned purposes. A comparison of these techniques concerning their capacity of identification and quantification of bond defects; however, still needs a comprehensive review. In this paper, a detailed comparison of several non-destructive testing techniques is provided. Emphasis is placed to institute a guideline to select the most suitable technique for the identification of zones with bond defects in laminated composites. Experimental tests on different composite based machined components are also discussed in detail. The discussion provides practical evidence about the effectiveness of different non-destructive testing techniques.N/

Exogenous WNT5A and WNT11 proteins rescue CITED2 dysfunction in mouse embryonic stem cells and zebrafish morphants

Mutations and inadequate methylation profiles of CITED2 are associated with human congenital heart disease (CHD). In mouse, Cited2 is necessary for embryogenesis, particularly for heart development, and its depletion in embryonic stem cells (ESC) impairs cardiac differentiation. We have now determined that Cited2 depletion in ESC affects the expression of transcription factors and cardiopoietic genes involved in early mesoderm and cardiac specification. Interestingly, the supplementation of the secretome prepared from ESC overexpressing CITED2, during the onset of differentiation, rescued the cardiogenic defects of Cited2-depleted ESC. In addition, we demonstrate that the proteins WNT5A and WNT11 held the potential for rescue. We also validated the zebrafish as a model to investigate cited2 function during development. Indeed, the microinjection of morpholinos targeting cited2 transcripts caused developmental defects recapitulating those of mice knockout models, including the increased propensity for cardiac defects and severe death rate. Importantly, the co-injection of anti-cited2 morpholinos with either CITED2 or WNT5A and WNT11 recombinant proteins corrected the developmental defects of Cited2-morphants. This study argues that defects caused by the dysfunction of Cited2 at early stages of development, including heart anomalies, may be remediable by supplementation of exogenous molecules, offering the opportunity to develop novel therapeutic strategies aiming to prevent CHD.Agência financiadora: Fundação para a Ciência e a Tecnologia (FCT) Comissão de Coordenação e Desenvolvimento Regional do Algarve (CCDR Algarve) ALG-01-0145-FEDER-28044; DFG 568/17-2 Algarve Biomedical Center (ABC) Municipio de Louléinfo:eu-repo/semantics/publishedVersio

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Background: Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active disease (HAD) by the American Academy of Neurology Practice Guidelines, and the label indication in Europe was recently restricted to the treatment of HAD patients. There is currently no consensus definition for HAD, and alemtuzumab efficacy across various HAD definitions has not been explored previously. Objectives: In this post hoc analysis, we assess the efficacy and safety of alemtuzumab in Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) trial patients who met criteria for at least one of four separate definitions of HAD (one primary and three alternatives). Over 2 years, alemtuzumab-treated HAD patients were compared with SC IFNB-1a-treated HAD patients, with additional 7-year follow-up in patients from the alemtuzumab arm. Methods: Patients in the CARE-MS studies received either alemtuzumab (baseline: 5 days; 12 months later: 3 days) or SC IFNB-1a (3 times weekly). Alemtuzumab-treated patients who enrolled in the extensions could receive additional courses ≥ 12 months apart. Four definitions of HAD were applied to assess alemtuzumab efficacy: the pre-specified primary definition (two or more relapses in the year prior to baseline and at least one gadolinium [Gd]-enhancing lesion at baseline) and three alternative definitions that focused on relapse, magnetic resonance imaging (MRI), or prior treatment response criteria. Efficacy outcomes were annualized relapse rate, change in Expanded Disability Status Scale score, 6-month confirmed disability worsening, 6-month confirmed disability improvement, MRI disease activity, and brain volume change. Adverse events were summarized for HAD patients meeting the primary definition. Results: In the pooled CARE-MS population, 208 alemtuzumab-treated patients met the primary HAD definition. Annualized relapse rate was 0.27 in years 0–2 and 0.16 in years 3–9. Over 9 years, 62% of patients were free of 6-month confirmed disability worsening, 50% had 6-month confirmed disability improvement, and median cumulative change in brain volume was − 2.15%. During year 9, 62% had no evidence of disease activity, and 69% were free of MRI disease activity. Similar efficacy outcomes were observed using an alternative relapse-driven HAD definition. For patients meeting alternative HAD definitions focused on either higher MRI lesion counts or disease activity while on prior therapy, reduced efficacy for some endpoints was seen. Safety was consistent with the overall CARE-MS population through year 9. Conclusions: Over 9 years, alemtuzumab efficacy was maintained in CARE-MS HAD patients based on four HAD definitions. These results support intervention with alemtuzumab in patients with early indicators of HAD, including frequent relapse without high MRI activity. No safety signals were observed over 9 years that were unique to the HAD populations. ClinicalTrials.gov Identifiers: NCT00530348; NCT00548405; NCT00930553; NCT02255656

Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury

Renal ischemia-reperfusion (I/R) injury is a major cause of acute kidney injury (AKI). Non-coding RNAs are crucially involved in its pathophysiology. We identified hypoxia-induced long non-coding RNA Malat1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) to be upregulated in renal I/R injury. We here elucidated the functional role of Malat1 in vitro and its potential contribution to kidney injury in vivo. Malat1 was upregulated in kidney biopsies and plasma of patients with AKI, in murine hypoxic kidney tissue as well as in cultured and ex vivo sorted hypoxic endothelial cells and tubular epithelial cells. Malat1 was transcriptionally activated by hypoxia-inducible factor 1-a. In vitro, Malat1 inhibition reduced proliferation and the number of endothelial cells in the S-phase of the cell cycle. In vivo, Malat1 knockout and wildtype mice showed similar degrees of outer medullary tubular epithelial injury, proliferation, capillary rarefaction, inflammation and fibrosis, survival and kidney function. Small-RNA sequencing and whole genome expression analysis revealed only minor changes between ischemic Malat1 knockout and wildtype mice. Contrary to previous studies, which suggested a prominent role of Malat1 in the induction of disease, we did not confirm an in vivo role of Malat1 concerning renal I/Rinjury